1.Visual analysis on minimally invasive treatment of liver cancer based on Cite Space biblio-metric study
Shupeng SHI ; Jiuxiang CHANG ; Taofei ZENG ; Hao HE ; Dalong YIN
Chinese Journal of Digestive Surgery 2023;22(9):1139-1146
Primary liver cancer is a malignant tumor with high morbidity and mortality in the world, and it is also a common malignant tumor of digestive tract in China. With the development of medical technology and the deepening of minimally invasive concept, minimally invasive therapy has gradually become the main treatment of liver cancer. Through the visual analysis of Cite Space bibliometrics study, the authors visually show the basic knowledge structure and evolution in the field of minimally invasive treatment of liver cancer, and explore the frontier hotspots and future development trends, so as to provide reference for scientific research and application in this field.
2.Application and prospect of artificial intelligence in the diagnosis and treatment of primary liver cancer
Chinese Journal of Digestive Surgery 2024;23(2):236-241
Primary liver cancer (hereinafter referred to as liver cancer) is one of the most common and deadly malignancies, posing a serious threat to human health. In recent years, advance-ments in artificial intelligence (AI) have opened up possibilities for the comprehensive enhancement of liver cancer diagnosis and treatment. AI technologies in liver cancer mainly include the machine learning (ML) and the deep learning (DL) models, with DL being a subtype of ML based on neural network structures. The application of ML and DL models in liver cancer has demonstrated tremen-dous potential, but there are still many issues that need to be addressed, including enhancing the generalizability and interpretability of results. The authors elaborate on the application progress of AI in the field of liver cancer in recent years, and explore the current challenges and future explora-tion directions.
3. Establishment of a multiplex PCR for rapid identification of Mycobacterium species
Shupeng YIN ; Chenqi YAN ; Zhiguang LIU ; Xiuqin ZHAO ; Xiaoqin LI ; Machao LI ; Haican LIU ; Yongliang LOU ; Kanglin WAN
Chinese Journal of Microbiology and Immunology 2019;39(10):771-777
Objective:
To establish and evaluate a multiplex PCR method for rapid identification of
4. Application of ARIMA model in predicting the incidence of tuberculosis in China from 2018 to 2019
Chenqi YAN ; Ruibai WANG ; Haican LIU ; Yi JIANG ; Machao LI ; Shupeng YIN ; Tongyang XIAO ; Kanglin WAN ; Weiqing RANG
Chinese Journal of Epidemiology 2019;40(6):633-637
Objective:
Autoregressive integrated moving average (ARIMA) model was used to predict the incidence of tuberculosis in China from 2018 to 2019, providing references for the prevention and control of pulmonary tuberculosis.
Methods:
The monthly incidence data of tuberculosis in China were collected from January 2005 to December 2017. R 3.4.4 software was used to establish the ARIMA model, based on the monthly incidence data of tuberculosis from January 2005 to June 2017. Both predicted and actual data from July to December 2017 were compared to verify the effectiveness of this model, and the number of tuberculosis cases in 2018-2019 also predicted.
Results:
From 2005 to 2017, a total of 13 022 675 cases of tuberculosis were reported, the number of pulmonary tuberculosis patients in 2017 was 33.68% lower than that in 2005, and the seasonal character was obvious, with the incidence in winter and spring was higher than that in other seasons. According to the incidence data from 2005 to 2017, we established the model of ARIMA (0,1,2)(0,1,0)12. The relative error between the predicted and actual values of July to December 2017 fitted by the model ranged from 1.67% to 6.80%, and the predicted number of patients in 2018 and 2019 were 789 509 and 760 165 respectively.
Conclusion
The ARIMA (0, 1, 2)(0, 1, 0)12 model well predicted the incidence of tuberculosis, thus can be used for short-term prediction and dynamic analysis of tuberculosis in China, with good application value.